HDAC6 and breast carcinoma: These results suggest that proteasome inhibition with bortezomib in breast cancer cells induces compensatory aggresomal protein degradation which can be blocked by WT161 via HDAC6 inhibition, thereby triggering cell stress followed by apoptotic cell death.